Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

A targeted pill before surgery shrank tumors in many with ALK-positive lung cancer

☕ Includes a question for the family ↓

Lung cancerPart of a story we are following · 12 articles · See every update
Cyclist riding a mountain bike up a rocky trail in Spain on a sunny day.
Cyclist riding a mountain bike up a rocky trail in Spain on a sunny day.Photo: Gongafa / Wikimedia Commons, CC0

If you or someone close to you has stage III lung cancer, this trial offers a hopeful signal. In a study of 33 people with stage III ALK-positive lung cancer, a targeted pill taken for 8 weeks before surgery left 10% or less living tumor in the removed tissue for 14 of them (42%).

This was an early-stage trial, so it does not change standard care yet. It does show that this approach is workable and active in people with stage III disease, which has no single best treatment.

What does ALK-positive mean?

Some lung cancers carry a change in a gene called ALK. Doctors can find it by testing the tumor. A cancer with this change is called ALK-positive.

The pill in this trial, alectinib, is a targeted drug aimed at that change. Targeted drugs are different from standard chemotherapy. They are built to go after one specific feature of the cancer.

Stage III means the cancer has spread beyond the lung into nearby areas, but surgery may still be possible. The authors note that stage III disease varies a lot and has no single best treatment.

How the study worked

The ALNEO trial enrolled 33 people with stage III ALK-positive non-small cell lung cancer who had not been treated before and whose tumors might be removable. Everyone took alectinib for 8 weeks, then had surgery, then took more alectinib for up to 96 weeks. The results were published on November 20, 2026 in the J Clin Oncol. The study was small, had no comparison group, and followed people for a median of about 27 months, so it cannot yet show who lives longer.

What they found

All 33 people finished the 8 weeks of pills before surgery. Tumors shrank in about two-thirds of them (67%).

Surgery followed for 28 people (85%). Most had a lobectomy, which removes one section of the lung. In 24 of those 28 (86%), surgeons removed the tumor with clean edges, with no cancer cells seen at the border of the removed tissue.

The main goal of the trial was something called a major pathologic response. That means 10% or less living tumor cells were left when the removed tissue was examined. This happened in about 4 in 10 people, exactly 14 of 33 (42%). Four people (12%) had no living tumor cells left at all.

After the surgery, 26 people (79%) went on to take alectinib again. Over the follow-up, six people (18%) saw their cancer come back. The median times before the cancer returned or before death were not reached. That means more than half of the group had not yet reached those points when the data were collected.

Side effects were mostly manageable. Serious ones, called grade 3 or higher, happened in 9% of people during the pills before surgery and in 27% during the pills after surgery.

The researchers concluded that alectinib before and after surgery is a feasible and active approach for this group.

What this means for you

This result does not mean every person with lung cancer should expect the same outcome. It applies to people whose tumors carry the ALK change. And because everyone in the trial took the pill, larger studies are still needed to compare it with other treatments.

Still, it shows that a drug aimed at one feature of the tumor was a feasible and active approach before surgery in this group.

What you can do today

If you or a loved one is facing stage III lung cancer, ask the care team whether the tumor has been tested for changes such as ALK, and what the results mean for treatment choices.

For clinicians and researchers

Design: Open-label, single-arm, multicenter phase II trial in 33 treatment-naïve patients with potentially resectable stage III ALK-positive NSCLC (median age 62 years, 70% female). Neoadjuvant alectinib 600 mg twice daily for 8 weeks, surgery, then adjuvant alectinib for up to 96 weeks; median follow-up 26.8 months.

Main result: Major pathologic response (primary end point, blinded central review) occurred in 14 patients (42%; 95% CI, 26 to 61), including four pathologic complete responses (12%; 95% CI, 3 to 28). ORR was 67%; the trial met its primary end point.

Main limitation: Single-arm design without a comparator, with only 33 patients; median EFS, DFS and OS were not reached, so survival benefit cannot be judged. Major pathologic response is a surrogate end point.

How it fits: Like the earlier article on a team-guided plan for tricky lung cancer reaching curative care, this supports tailored treatment sequencing for stage III disease, here with a targeted drug before surgery. Two pills beat chemotherapy for EGFR lung cancer that escapes through MET · A team-guided plan got most people with tricky lung cancer to curative care

Open question: Whether perioperative alectinib improves EFS and OS compared with standard approaches remains untested, as does the optimal duration of neoadjuvant and adjuvant treatment.

Talk about it at home

Every cell in your body follows an instruction book called genes, and sometimes a single line gets a little typo. Scientists studied people whose cells had one particular typo and tested a special helper made to fit only that spot, like a key cut for a single lock. Then they looked very closely at what had changed, to see whether the idea really worked.

Try it at home

Look up together how scientists read the tiny letters of DNA, and see if you can find a picture of its famous twisted ladder shape. Then decide which part of the picture looks most like a page from an instruction book.

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. A targeted pill before surgery shrank tumors in many with ALK-positive lung cancer. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/alectinib-before-surgery-alk-positive-lung-cancer/
Vancouver
Mongevity Desk. A targeted pill before surgery shrank tumors in many with ALK-positive lung cancer [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/alectinib-before-surgery-alk-positive-lung-cancer/
APA
Mongevity Desk. (2026, November 21). A targeted pill before surgery shrank tumors in many with ALK-positive lung cancer. Mongevity. https://mongevity.science/cancer/2026/11/alectinib-before-surgery-alk-positive-lung-cancer/
For your website
<a href="https://mongevity.science/cancer/2026/11/alectinib-before-surgery-alk-positive-lung-cancer/">A targeted pill before surgery shrank tumors in many with ALK-positive lung cancer</a>

Free to share or quote with credit and a link.

Questions and answers

What is ALK-positive lung cancer?
It is a non-small cell lung cancer whose cells carry a change in a gene called ALK. A test on the tumor can find it.
How well did the pill work before surgery?
Tumors shrank in about two-thirds of people (67%). Among all 33 people, 14 (42%) had 10% or less living tumor left in the removed tissue.
Is this the standard treatment now?
No. This was a small phase II trial with one group and no comparison group. Larger studies are needed before it could become standard care.
Were there serious side effects?
Serious side effects happened in 9% of people during the pills before surgery and 27% during the pills after surgery.

Sources

  1. J Clin Oncol: Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316) (PMID 43063368 · DOI 10.1200/jco-26-00854) · 2026-11-21

More on this story

Report an error